A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration

In many countries, a second dose of a combined measles, mumps, and rubella (MMR) vaccine is recommended at 4–6 years of age – similarly to the booster of diphtheria, tetanus, acellular pertussis, and inactivated polio vaccine (DTaP-IPV) and the second dose of varicella vaccine (VV). Vaccine co-admin...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605865/
https://www.ncbi.nlm.nih.gov/pubmed/30785357
http://dx.doi.org/10.1080/21645515.2018.1554971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605865/
https://www.ncbi.nlm.nih.gov/pubmed/30785357
http://dx.doi.org/10.1080/21645515.2018.1554971

Ejemplares similares